Trevi Therapeutics, Inc.

[On Demand]
Search General Info
Search Education
Search Partnering Companies
We are developing Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions by targeting the central and peripheral nervous systems.

Our novel investigational oral formulation has the potential to unlock new market opportunities and significantly improve the quality of life of patients who currently have few treatment options. Haduvio™ is an oral, extended-release formulation of nalbuphine, which has a long history of efficacy and safety, having been approved for more than 20 years in the United States and Europe as a subcutaneous injection for relief of moderate to severe pain in the hospital setting.

We are conducting a Phase 2b/3 clinical trial, PRISM, for the treatment of chronic pruritus associated with prurigo nodularis and a Phase 2 trial, CANAL, for chronic cough in patients with idiopathic pulmonary fibrosis (IPF). We are in the planning stages of a Phase 2 study for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease.
Ticker:
TRVI
Exchange:
NASDAQ
Company Type:
Publicly Traded Company
Company HQ State:
Connecticut
Company HQ Country:
United States
Year Founded:
2011
Main Therapeutic Focus:
Lead Product in Development:
Nalbuphine ER Oral Tablets
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
photo
President & CEO
Trevi Therapeutics